Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • A.M. Oza - (Author)
  • A.D. Cook - (Author)
  • J. Pfisterer - (Author)
  • A. Embleton - (Author)
  • J.A. Ledermann - (Author)
  • E. Pujade-Lauraine - (Author)
  • G. Kristensen - (Author)
  • M.S. Carey - (Author)
  • P. Beale - (Author)
  • A. Cervantes - (Author)
  • T.W. Park-Simon - (Author)
  • G. Rustin - (Author)
  • F. Joly - (Author)
  • M.R. Mirza - (Author)
  • M. Plante - (Author)
  • M. Quinn - (Author)
  • A. Poveda - (Author)
  • G.C. Jayson - (Author)
  • D. Stark - (Author)
  • A.M. Swart - (Author)
  • L. Farrelly - (Author)
  • R. Kaplan - (Author)
  • M.K. Parmar - (Author)
  • T.J. Perren - (Author)
  • ICON7 TrIal InvesTIgaTors - (Author)
  • U. Canzler - , Department of Gynecology and Obstetrics (Author)
  • P. Wimberger - , Department of Gynecology and Obstetrics (Author)

Details

Original languageEnglish
Pages (from-to)928-936
Number of pages9
JournalThe Lancet Oncology
Publication statusPublished - 2015
Peer-reviewedYes

External IDs

Scopus 84938198626
researchoutputwizard legacy.publication#72071

Keywords

Sustainable Development Goals